Dermata Therapeutics, Inc. (DRMA)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
1.31 USD
-0.03
(-2.239%) ⇩
(April 21, 2026, 10:52 a.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:41 a.m. EDT
Dermata Therapeutics (DRMA) presents a high-risk trade fueled by speculative news surrounding a potential PIVOT to consumer skincare and immediate capital raises. While the recent $4.1M+ private placements have provided immediate liquidity and market hype, the fundamental reality remains critical: the company is illiquid (average volume < 1% of current day's), faces a bearsish short-term forecast suggesting significant potential downturn (-28.26%), and has no dividend or cash flow. The technology pivot is intriguing, but the valuation metrics (negative PE, -8.16 EPS) and lack of analyst coverage make investing in the long-term purely a bet on initial public offerings (IPO) or M&A, not organic growth. The current price of $1.36 is well below the 52-week high of $9.90 and trading significantly below its book value, despite shareholder dilution. Investors should view this as a 'speculative holding' rather than an investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.239845 |
| MSTL | 0.429422 |
| AutoETS | 0.434388 |
| AutoARIMA | 0.436123 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 71% |
| H-stat | 0.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.028 |
| Excess Kurtosis | 0.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 5,269,007 |
| Forward P/E | -0.34 |
| Beta | 0.50 |
| Website | https://www.dermatarx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.81232494 |
| Address1 | 3,525 Del Mar Heights Rd. |
| Address2 | Suite 332 |
| All Time High | 16,680.0 |
| All Time Low | 1.1 |
| Ask | 1.66 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 94,270 |
| Average Daily Volume3 Month | 2,035,485 |
| Average Volume | 2,035,485 |
| Average Volume10Days | 94,270 |
| Beta | 0.503 |
| Bid | 0.972 |
| Bid Size | 2 |
| Book Value | 2.34 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.31 |
| Current Ratio | 4.794 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.39 |
| Day Low | 1.29 |
| Display Name | Dermata Therapeutics |
| Earnings Timestamp End | 1,747,225,800 |
| Earnings Timestamp Start | 1,747,225,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -2,132,306 |
| Eps Forward | -3.87 |
| Eps Trailing Twelve Months | -8.16 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3204 |
| Fifty Day Average Change | -0.010400057 |
| Fifty Day Average Change Percent | -0.007876444 |
| Fifty Two Week Change Percent | -81.23249 |
| Fifty Two Week High | 9.9 |
| Fifty Two Week High Change | -8.59 |
| Fifty Two Week High Change Percent | -0.8676768 |
| Fifty Two Week Low | 1.1 |
| Fifty Two Week Low Change | 0.20999992 |
| Fifty Two Week Low Change Percent | 0.19090901 |
| Fifty Two Week Range | 1.1 - 9.9 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,628,861,400,000 |
| Float Shares | 2,930,855 |
| Forward Eps | -3.87 |
| Forward P E | -0.33850127 |
| Free Cashflow | -5,016,645 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.24816999 |
| Held Percent Institutions | 0.04498 |
| Implied Shares Outstanding | 4,022,143 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-08-13 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,754,006,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. |
| Long Name | Dermata Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,269,007 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_283634456 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -7,558,557 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,490,225 |
| Number Of Analyst Opinions | 1 |
| Open | 1.38 |
| Operating Cashflow | -7,757,559 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 800 2543 |
| Previous Close | 1.34 |
| Price Hint | 4 |
| Price To Book | 0.55982906 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.585 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03000009 |
| Regular Market Change Percent | -2.2388127 |
| Regular Market Day High | 1.39 |
| Regular Market Day Low | 1.29 |
| Regular Market Day Range | 1.29 - 1.39 |
| Regular Market Open | 1.38 |
| Regular Market Previous Close | 1.34 |
| Regular Market Price | 1.31 |
| Regular Market Time | 1,776,783,178 |
| Regular Market Volume | 14,911 |
| Return On Assets | -0.85253996 |
| Return On Equity | -1.94196 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,022,143 |
| Shares Percent Shares Out | 0.0656 |
| Shares Short | 264,037 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 112,575 |
| Short Name | Dermata Therapeutics, Inc. |
| Short Percent Of Float | 0.0838 |
| Short Ratio | 0.12 |
| Source Interval | 15 |
| State | CA |
| Symbol | DRMA |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 7,521,978 |
| Total Cash Per Share | 1.87 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.521475 |
| Two Hundred Day Average Change | -2.2114751 |
| Two Hundred Day Average Change Percent | -0.6279968 |
| Type Disp | Equity |
| Volume | 14,911 |
| Website | https://www.dermatarx.com |
| Zip | 92,130 |